Leqembi IQLIK (subcutaneous) causes systemic reactions in under 1% of patients versus 26% for IV infusions, making it substantially more tolerable despite requiring weekly self-injections.
WHO's 2026 guidelines show that 45% of dementia cases could be prevented through modifiable factors like exercise, social connection, and cognitive activity—even starting at 65.
See which older adults fit the strongest evidence—and why hearing aids should not be presented as dementia prevention.
Build a smoke-day routine for outdoor activity, car travel and cleaner indoor air without overstating the dementia evidence.
Practical, source-based steps for taking a loved one with dementia into restaurants, cafés, and other public settings with less stress.
Learn the onset, awareness, and treatment-response clues doctors use to separate treatable depression from progressive dementia.
A clear 2026 comparison of Leqembi and Kisunla — dosing, ARIA risks, monitoring, and the finite-course versus maintenance choice.
How the FDA's July 2026 at-home lecanemab autoinjector works, who qualifies, and the ARIA safety monitoring it still demands.
A clear-eyed look at what the shingles-vaccine-and-dementia research really shows, its limits, and what to do about it.
How social isolation affects dementia risk—and small, realistic steps to rebuild connection and mental engagement.